A blood test to detect which people with failing memories will go on to develop Alzheimer’s disease has been developed by British scientists, who hope it may prove a breakthrough in the hunt for a cure.
After a decade’s work, an international collaboration led by scientists from King’s College London, with the UK company Proteome Sciences, has published a study identifying a set of 10 proteins in the blood. The test can predict the onset of Alzheimer’s in the next 12 months in people with memory problems with an accuracy of 87 percent. It could cost £100 to £300 and be available within two years.
Alzheimer’s and other forms of dementia are distressing and a huge burden on those affected, their families and health services. However, despite the growing problem as people live longer, there are no good long-term treatments and there is no cure. British Prime Minister David Cameron recently announced a drive to discover new drugs for dementia, which he said “stands alongside cancer as one of the greatest enemies of humanity.”
As one potential drug after another has fallen by the wayside, scientists have begun to look for ways to treat people at a much earlier stage, when their brain is not so badly damaged. However, to do that, they need a test to predict who is going to develop the disease.
Scientists in the US published details in March of a proposed test for lipids (fatty chemicals) in the blood of people in the general population who do not have memory problems. However, such a screening test would be controversial: Few healthy people want to know they may be in line for an incurable disease that can be neither prevented nor treated.
The new test is aimed at people with the kind of memory loss called mild cognitive impairment, 60 percent of whom will go on to develop dementia. Those are the people scientists now want to recruit into trials to prevent, or at least delay, the onset of Alzheimer’s.
“Alzheimer’s begins to affect the brain many years before patients are diagnosed with the disease,” King’s College professor Simon Lovestone said. “Many of our drug trials fail because by the time patients are given the drugs, the brain has already been too severely affected.”
“A simple blood test could help us identify patients at a much earlier stage to take part in new trials and hopefully develop treatments which could prevent the progression of the disease,” he added.
The researchers investigated 26 proteins which have all been linked to Alzheimer’s in the past. Writing in the journal Alzheimer’s & Dementia, they say they took blood samples from 1,148 individuals, of whom 476 had Alzheimer’s disease, 220 had mild cognitive impairment and 452 were elderly, but without dementia.
They found that 16 of the proteins were associated with brain shrinkage either in mild cognitive impairment or Alzheimer’s.
In a second set of tests, they identified 10 proteins whose presence could predict, with a reasonable degree of accuracy, whether people with mild cognitive impairment would develop Alzheimer’s within a year.
Larger trials involving 5,000 to 10,000 people are still needed, the scientists say.
“The next step will be to validate our findings in further sample sets, to see if we can improve accuracy and reduce the risk of misdiagnosis, and to develop a reliable test suitable to be used by doctors,” Lovestone said.
Other scientists were enthusiastic about the potential for the test to aid drug discovery, but cautious about its potential use for diagnosing the disease in otherwise healthy people.
Eric Karran, science director at the charity Alzheimer’s Research UK, which helped fund the research, said a test identifying those at risk of Alzheimer’s at an early stage would be of “real value,” but warned that it would have to be used responsibly.
“Alzheimer’s disease is now the most feared diagnosis,” he said. “We have to be very careful about how we use these tests, especially in the absence of effective therapy.”
“Finding a way to detect dementia before symptoms develop would revolutionize research into the condition... However, this research does not mean that a blood test for dementia is just around the corner,” Alzheimer’s Society head of research James Pickett said.
“These 10 proteins can predict conversion to dementia with less than 90 percent accuracy, meaning one in 10 people would get an incorrect result. Therefore, accuracy would need to be improved before it could be a useful diagnostic test,” he added.
Republican US lawmakers on Friday criticized US President Joe Biden’s administration after sanctioned Chinese telecoms equipment giant Huawei unveiled a laptop this week powered by an Intel artificial intelligence (AI) chip. The US placed Huawei on a trade restriction list in 2019 for contravening Iran sanctions, part of a broader effort to hobble Beijing’s technological advances. Placement on the list means the company’s suppliers have to seek a special, difficult-to-obtain license before shipping to it. One such license, issued by then-US president Donald Trump’s administration, has allowed Intel to ship central processors to Huawei for use in laptops since 2020. China hardliners
Conjoined twins Lori and George Schappell, who pursued separate careers, interests and relationships during lives that defied medical expectations, died this month in Pennsylvania, funeral home officials said. They were 62. The twins, listed by Guinness World Records as the oldest living conjoined twins, died on April 7 at the Hospital of the University of Pennsylvania, obituaries posted by Leibensperger Funeral Homes of Hamburg said. The cause of death was not detailed. “When we were born, the doctors didn’t think we’d make 30, but we proved them wrong,” Lori said in an interview when they turned 50, the Philadelphia Inquirer reported. The
RAMPAGE: A Palestinian man was left dead after dozens of Israeli settlers searching for a missing 14-year-old boy stormed a village in the Israeli-occupied West Bank US President Joe Biden on Friday said he expected Iran to attack Israel “sooner, rather than later” and warned Tehran not to proceed. Asked by reporters about his message to Iran, Biden simply said: “Don’t,” underscoring Washington’s commitment to defend Israel. “We are devoted to the defense of Israel. We will support Israel. We will help defend Israel and Iran will not succeed,” he said. Biden said he would not divulge secure information, but said his expectation was that an attack could come “sooner, rather than later.” Israel braced on Friday for an attack by Iran or its proxies as warnings grew of
IN PURSUIT: Israel’s defense minister said the revenge attacks by Israeli settlers would make it difficult for security forces to find those responsible for the 14-year-old’s death Israeli Prime Minister Benjamin Netanyahu on Saturday condemned the “heinous murder” of an Israeli teenager in the occupied West Bank as attacks on Palestinian villages intensified following news of his death. After Benjamin Achimeir, 14, was reported missing near Ramallah on Friday, hundreds of Jewish settlers backed by Israeli forces raided nearby Palestinian villages, torching vehicles and homes, leaving at least one villager dead and dozens wounded. The attacks escalated in several villages on Saturday after Achimeir’s body was found near the Malachi Hashalom outpost. Agence France-Presse correspondents saw smoke rising from burned houses and fields. Mayor Amin Abu Alyah, of the